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Abstract Rapid and quantitative prostate-specific antigen
(PSA) biomarker detection would be beneficial to cancer di-
agnostics, improving early detection and therefore increasing
chances of survival. Nanoparticle-based detection is routinely
used in one-step nitrocellulose-based lateral flow (LF) immu-
noassays; however, it is well established within the scientific
diagnostic community that LF technology lacks sensitivity for
measuring biomarkers, such as prostate-specific antigen
(PSA). A trend in point-of-care (POC) protein biomarker
quantitation is the miniaturization of immunoassays in
microfluidic devices. This work aimed at testing the feasibility
of carbon and gold nanoparticles as immunoassay labels for
PSA detection with cost-effective optical detection in a novel
microfluidic POC platform called microcapillary film (MCF),
cons is t ing of a para l le l ar ray of f luoropolymer
microcapillaries with 200-μm internal diameter. With
neutravidin-coated carbon, nanoparticles were able to quantify
an immobilized biotinylated monoclonal antibody (coating
solution from 10 to 40 μg/ml) and PSA was successfully
quantified in a sandwich assay using silver-enhanced gold
nanoparticles and a flatbed scanner; yet, the dynamic range
was limited to 10–100 ng/ml. Although direct optical detec-
tion of PSAwithout enzymatic amplification or fluorophores
is possible and technically appealing for the simplified fluidics
and signal scanning setups involved, ultimately, the binding of
a thin layer of nanoparticles onto the wall of transparent
microcapillaries is not sufficient to cause a significant drop
on the optical colorimetric signal. Future studies will explore
the use of fluorescence nanoparticles.
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1 Introduction
A point-of-care (POC) test has to be sensitive, capable of
detecting a broader number of clinical conditions, and the
simplicity of use should approach that of a nitrocellulose lat-
eral flow test (LF). Heterogeneous immunoassays, where the
free analyte is separated from the bound forming the antibody-
antigen complex, are the most sensitive bioanalytical tools
used in clinical diagnostics. However, when translated to
POC format, the sensitivity of the test is often compromised
by the required level of simplicity and speed of the assay, in
addition to the need of using small volumes of complex bio-
logical matrices (sample) and low-cost optical scanning [1].
In most heterogeneous sandwich immunoassays, the
antibody-antigen complex is quantified through label detec-
tion. The label conjugated to a detection antibody (DetAb)
generates a signal which is proportional to the concentration
of antigen. The nature of signal depends on the label used
which in turn defines the readout system to be used. These
two aspects work together establishing the overall sensitivity
of the assay.
The first labels used in immunoassays were radioactive
isotopes, such as iodine-125 [2]. However, due to concerns
about radioactivity exposure, disposal of radioactive waste
and instability of radiolabels reagents, other labels were
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deve loped . [3 ] Enzymes [4] , f luorophores [5 ] ,
chemiluminophores [6], microparticles [7] and quantum dots
[8] have been extensively applied to signal generation in im-
munoassay tests including miniaturized microfluidic devices.
Enzymes are the most widely used label due to their flexibility
and unique amplification power. Different enzymes are avail-
able that can generate coloured, fluorescent or luminescent
products from a transparent substrate. Enzymes are strong
signal amplifiers, which are established by the turnover num-
ber. A single enzyme molecule can convert up to 107 mole-
cules of substrate per minute [2]. However, enzymes are not
suitable for one-step immunoassays, as they require more
complex washings and the use of multiple reagents.
LF immunoassays are a well-established technology for
one-step POC testing, and current applications include detec-
tion of pregnancy hormone (hCG), malaria and HIV.
Nevertheless, LF technology lacks sensitivity which disables
it to diagnose certain clinical conditions that demand sensitive
quantitation of biomarkers. This is the case with different types
of cancer biomarkers including prostate-specific antigen (PSA),
which presents a clinical threshold of 4 ng/ml for biopsy [9] and
0.4 ng/ml for monitoring cancer recurrence after radical pros-
tatectomy [10–14]. The POC detection of protein biomarkers
like PSA is in need of simple and rapid tests that preferably use
a drop of blood collected from a finger prick or from an intra-
venous blood sample or other biological sample (e.g. urine) and
a very simple fluidic setup, ideally as one-step immunoassay [1,
15]. Microfluidic tests qualify to fill up this gap since they are
able to precisely control the flow and use a broader range of
sample volumes. However, translating LF assays into
microfluidic platforms poses several technical challenges.
LF traditionally uses a label directly conjugated to the
DetAb without the need of signal amplification. The sample
is placed on a sample pad, moving through by capillary action,
mixes with the labelled antibody in the conjugated pad, and
continues to flow through the test zone [16]. The density of
labelled particles in the test zone generates a signal propor-
tional to the analyte concentration. LF technology uses porous
membranes, such as nitrocellulose, which present a very large
surface area even in a very small test zone (1-mm width line).
Translating one-step immunoassays into microfluidic plat-
forms with a much lower order of magnitude of surface area
in the detection zone can be challenging, probably
compromising the sensitivity of the test.
Traditionally, particles have been used as labels in
microfluidic systems, yet the readout system has to be sophis-
ticated or amplification methods have to be applied [17, 18].
To combine good sensitivities with multiplex capability,
microfluidic systems often use fluorophores as labels, which
cannot be considered particles. Despite this, signal detection
from fluorescent labels requires the use of complex and ex-
pensive equipment, such as fluorescent microscopes, flow
cytometers and fluorescent scanners [5, 19].
Few examples of microfluidic immunoassays can be found
in literature which used particles as labels and low-cost read-
out systems. Yet C. et al. (2009) [20] reported a protein A
sandwich immunoassay where the capture antibody (CapAb)
was immobilized onto glass slides, surrounded by a polydi-
methylsiloxane (PDMS) structure. The DetAb, conjugated
with platinum nanoparticles, generated a signal which was
subsequently enforced by a silver enhancement step. The
signal was detected by a flatbed scanner with a reported limit
of detection (LoD) of the assay in the order of 1 ng/ml [20]. Lu
Y. et al. (2009) [21] reported a human IgG/anti-IgG assay,
with IgG immobilized onto the polystyrene surface inside
PDMS channels, with the DetAb labelled with gold nanopar-
ticles and also silver enhanced. The test was optically scanned
with a cell phone camera, with a LoD of approximately 1 ng/
ml [21]. PSA presented a LoD of 5 × 10−4 pM with a
biobarcode using the Verigene ID scanning system. [22]
Understanding how particle labels can be detected with
low-cost readout systems can be transformative to
microfluidic immunoassays, bringing them closer to an ideal
POC diagnostic test.
Recently, PSA has been quantified using a ‘lab-in-a-brief-
case’ and portable smartphone detection with colorimetric and
fluorescent multistep enzymatic amplification achieving a
LoD of 0.08 to 0.9 ng/ml [23, 24]. In these assays, the detected
signal related to the whole capillary volume occupied by the
converted chromogenic or fluorescent substrate, which was
optically scanned with low-cost detection readers. This pres-
ent work aims reducing the number of assay steps by
eliminating the enzymatic reaction and performing direct
detection of nanoparticle labels adsorbed on the capil-
lary wall.
This paper reports for the first time the use of two different
particle labels, carbon nanoparticles [25] and gold nanoparti-
cles for optical quantitation of PSA in transparent plastic
microcapillary film (MCF, Fig. 1). Carbon nanoparticles have
been reported to be 100 and 10 times more sensitive than
standard gold nanoparticles and silver enhanced gold nanopar-
ticles, respectively. For this reason, both types of nanoparticles
were used in this study in order to find the optimum label for
PSA detection [26]. The binding of nanoparticles to the inner
walls of the microcapillaries pre-coated with CapAb causes an
optical diffraction, resulting in a drop of the optical colorimet-
ric signal. Optical nanoparticle detection of PSA and other
biomarkers in microcapillaries can potentially help reducing
the assay time and complexity of the overall assay, bringing
these microfluidic tests closer to a POC format (Fig. 2a). The
MCF is amelt-extruded fluorinated ethylene propylene (FEP) -
Teflon flat film, with 10 parallel microcapillaries with 200 μm
mean internal diameter. This geometry offers a similar surface
area as a microwell in a 96-well plate, considering a 1-cm long









Fig. 1 Microcapillary film
(MCF) immunoassay platform. a
Close look of MCF. b
Microphotograph of MCF
showing the transparency of the
FEP-Teflon polymer and the 10
parallel capillaries with 200-μm
diameter average. c Optical
interrogation of MCF
immunoassay test strips
Fig. 2 Nanoparticle-labelled assay methodology in the MCF platform.
The MCF is attached to a syringe and inserted into a well with a reagent
solution (1), 200 μl of that solution is aspirated (2) and the reagent will be
aspirated from the adjacent well (3). a Our vision for a simple two-step
MCF assay. b Assay methodology performed in the present experimental
work, described in Section 2.3
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2 Materials and Methods
2.1 Materials and Reagents
Purified anti-human IL-1β biotin and anti-human IL-1β were
supplied by e-Biosciences (Hatfield, UK). Anti-PSA CapAb
and anti-PSA DetAb conjugated with gold nanoparticles were
supplied by Wama Diagnóstica (São Carlos, Brazil). The sil-
ver enhancement kit was supplied by Sigma-Aldrich (Dorset,
UK). The PSA native protein was purchased from Abcam
(Cambridge, UK). The Carbon nanoparticles were supplied
by Wageningen Food and Biobased Research, Wageningen
University & Research (Wageningen, The Netherlands). The
particles cluster to irregular shapes with an average size of 150
to 200 nm.
Phosphate-buffered saline (PBS) and bovine serum albu-
min (BSA) were sourced from Sigma-Aldrich (Dorset, UK).
PBS pH 7.4, 10 mM was used as the main experimental buff-
er. The blocking solution consisted of 3% w/v protease-free
BSA diluted in PBS buffer. For washings, PBSwith 0.05% v/v
of Tween-20 (Sigma-Aldrich, Dorset, UK) was used. The
FEP-Teflon microcapillary film (MCF) is fabricated from
fluorinated ethylene propylene co-polymer by melt-extrusion
process by Lamina Dielectrics Ltd. (Billingshurst, West
Sussex, UK). FEP-Teflon MCF presents 10 bore parallel cap-
illaries with 223 ± 23-μm diameter.
2.2 Neutravidin-Coated Carbon Nanoparticle Detection
Four solutions of IL-1β biotinylated with 0, 10, 20, 40 and
80 μg/ml and one with 3% of BSAwere injected in different
capillaries using a 1-ml syringe attached with a needle (i.d.
200 μm) of a 24-cm MCF strip and incubated for 2 h at room
temperature. The biotinylated antibody solution was replaced
by 3% BSA solution incubated for 2 h at room temperature in
all the capillaries. The long MCF strip was trimmed in 4-cm
length strips and several dilutions of neutravidin conjugated
carbon nanoparticle solutions (1:1, 1:2, 1:5, 1:7, 1:10 and
1:50) were added to the different 4-cm MCF strips being in-
cubated for 2 h in an orbital shaker, followed by a washing
step with PBS Tween. The strips were then imaged with a
flatbed scanner (HP Scanjet G4050) in transmittance mode.
TheMCFwas cut exposing the surface area coated with the
carbon nanoparticles, gold-coated for 5 min with a gold sput-
ter cater/carbon evaporator and placed in a high-resolution
field emission gun scanning electron microscope (FEGSEM)
for imaging at several magnifications, being the highest is
15,000 KW.
2.3 Gold Nanoparticle Detection with Silver Enhancement
An MCF strip was filled with 40 μg/ml of anti-PSA CapAb
and incubated for 2 h at room temperature. The solution was
replaced by 3% BSA incubated for 2 h at room temperature.
After a washing step, the strip was trimmed in 4-cmMCF test
strips. Four MCF test strips were filled with 0, 10, 50 and
100 ng/ml of PSA native protein solutions and incubated for
10 min. A solution of 1:50 dilution of anti-PSA DetAb con-
jugated with gold nanoparticles (Fig. 2b) was incubated for
1 h in the orbital shaker followed by a washing step. The silver
enhancement solution was applied for 10 min at room temper-
ature and the fixing solution for 3 min followed by a distilled
water washing step. The MCF strips were imaged with the
flatbed scanner in transmittance mode (Fig. 1c).
2.4 MCF Image Analysis
RGB digital images were split into 3 separate channel images
by ImageJ software. The green channel images were used to
calculate absorbance values, based on the grey scale peak
height of each individual capillary of FEP-Teflon® MCF as
described previously [27, 28] and briefly illustrated in Fig. 1c.
The absorbance value on each individual microcapillary was
calculated based on Eq. (1):




where I is the grey scale peak height and I0 is the maximum
grey scale value. The absorbance values presented averages of
absorbance from 10 capillaries to one MCF stip.
3 Results and Discussion
3.1 The Use of Carbon Nanoparticles
The use of particles as labels instead of enzymes can bring
microfluidic systems closer to simple one-step POC diagnos-
tics, eliminating the time and complexity of multiple step im-
munoassays. Only few studies have been reported dealing
with particle detection in microfluidic systems with low-cost
detection systems. However, such systems are fundamental
for future development of affordable POC biomarker testing.
Carbon nanoparticles were used in LF assays for albumin
detection with a LoD of 0.25 μg/ml, and Kunitz-type for tryp-
sin inhibitor was detected with a LoD of 2.5 ng/ml in compet-
itive assay format [29]. A study that aimed to enhance the
detection limit of LF test through the evaluation and compar-
ison of bioconjugates reported a 10-fold improvement in sen-
sitivity for biotin-streptavidin systems and for dengue detec-
tion when compared with silver-coated gold nanoparticles
[26]. Carbon nanoparticles coated with neutravidin were the
first carbon particle system to be tested in the MCF platform.
Particles bound directly to immobilize biotinylated antibodies
and a dynamic range between 10 and 40 μg/ml of the biotin-
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antibody coating solution was observed by flatbed scanner.
Digital images were collected in transmittance mode and
followed by grey scale analysis (Fig. 3a, b). In the grey scale
image (Fig. 3b), it is possible to score the difference in the
refractive index of MCF capillary walls with and without par-
ticles attached.
The SEM images in Fig. 3 are coherent with the flatbed
scanner images showing an increment in the surface density of
carbon nanoparticles from 10 μg/ml and moving towards sat-
uration beyond 40–80 μg/ml biotin-antibody in the coating
solution. This showed that it is possible to detect carbon nano-
particles using a flatbed scanner as a readout system, however
requiring further optimization. Potentially, other detection sys-
tems should be tested in order to achieve better sensitivity and
apply this nanoparticle label to sandwich immunoassays.
Optimization started with screening the concentration of car-
bon nanoparticles and the results are shown in Fig. 4.
High concentrations of carbon nanoparticles were not ben-
eficial for molecular detection in the MCF as shown in Fig. 4,
as flatbed scanner images with a coating concentration of
40 μg/ml of biotinylated antibody showed no signal with un-
diluted or even 1:2 diluted carbon nanoparticles. In the SEM
images of microcapillaries (Fig. 4c), it is possible to see crys-
tals with an average perimeter size of 3 μm. Considering the
carbon particles are irregular in shape and present an average
size of 150 to 200 nm, we conclude that in certain conditions,
the carbon nanoparticles agglomerated, becoming larger and
more prone to be removed during the washing steps. Carbon
nanoparticles diluted above 1:50 are not recommended either,
as there is not enough surface density of particles to cause a
decrease in optical signal that is detected with the flatbed
scanner, despite the nanoparticles being clearly visible in the
SEM images (Fig. 4c). As can be seen in Fig. 4b, higher
signals were obtained with the carbon dilutions of 1:5 to
1:10, dilution 1:5 giving the best results.
Optimizing the carbon particle concentration would not be
enough to perform sensitive immunoassay in the MCF, as the
maximum surface density achieved is far from full surface
Fig. 3 Biotinylated antibody MCF-adsorbed detection with carbon
nanoparticles neutravidin coated (1:10 dilution). a MCF flatbed scanner
green channel digital image in transmittance mode, showing
microcapillaries coated with 80, 40, 20, 10 and 0 μg/ml of biotinylated
antibody, 1 to 5, respectively. b Corresponding grey scale showing the
concentrations of 80, 40, 20, 10 and 0 μg/ml of biotinylated antibody, 1 to
5, respectively. c Scanning electron microscope (SEM) pictures with 10,
20, 40 and 80 μg/ml of biotinylated antibody
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coverage and the total surface area available is not large
enough to promote an optical signal that can be detected e.g.
with naked eye. Thus, a full PSA sandwich immunoassay in
MCF with carbon nanoparticles was not attempted in this
study. Using different light sources and optical setup with a
portable camera could improve signal intensity of nanoparti-
cles in microcapillaries.
3.2 The Use of Gold Nanoparticle Label with Silver
Enhancement
The other nanoparticle system tested in the MCF platform for
PSA detection was the silver-enhanced gold nanoparticles. A
PSA sandwich assay was performed, and the results are
shown in Fig. 5. PSA is a prostate cancer biomarker with a
Fig. 5 Gold nanoparticle MCF IAs with silver enhancement. a Sandwich assay diagram with gold nanoparticle silver enhancement step. b PSA
response curve with gold nanoparticle silver enhanced; inset pictures show scanned images of the MCF strips
Fig. 4 Carbon nanoparticle neutravidin-coated detection of 40 μg/ml of
biotin-antibody in the MCF. a Flatbed scanner digital image of
microcapillaries with 40 μg/ml of biotin-antibody and several dilutions
of carbon nanoparticles 1, 2, 3, 4, 5 and 6 which correspond to 1:1, 1:2,
1:5, 1:7, 1:10 and 1:50, respectively. b Correspondent grey scale image
with previously mentioned dilutions of carbon nanoparticles and 40 μg/
ml of biotin-antibody. c Correspondent scanning electron microscope
(SEM) pictures with several dilutions of carbon nanoparticles
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clinical threshold of 4 ng/ml [9]. The data obtained showed a
significant difference between 0 ng/ml of PSA and the lowest
concentration of PSA tested, which was 10 ng/ml. This indi-
cates that the sensitivity of the assay may be improved upon
optimization of the assay. A 4PL (4 Parameters Logistic) mod-
el fitted the data with a cross correlation coefficient of 0.999.
However, the variability between capillaries of the sameMCF
test strip is 34% in the highest PSA concentration. This shows
that the concentration of gold nanoparticles might not be op-
timized yielding poor uniformity for higher PSA concentra-
tions, since there are not enough gold nanoparticles to bind to
all the antigens immobilized in the 10 capillaries. Alternative
optical setups will also be explored in the future for enhancing
signal-to-noise ratio.
To the best of our knowledge, this is the first time a cancer
biomarker (PSA in this case) is quantified using the silver-
enhanced gold nanoparticles in a microfluidic platform.
Although the silver enhancement results in a multistep assay,
particle labels are flexible, cost effective and will, therefore,
contribute to increase flexibility of microfluidic POC systems.
3.3 Limitations of Optical Detection with Nanoparticle
Labels
The limited sensitivity obtained in theMCFwith colloid nano-
particles in our studies is related to the limited concentration of
immobilized nanoparticles that are present in the microfluidic
channel during the optical scanning procedure. In the presence
of an antigen in the sample, nanoparticles conjugated with the
DetAb can be sandwiched to the surface of the
microcapillaries pre-coated with CapAb (Fig. 6a), which can
form a maximum of 400-ng/cm2 monolayer. On the best sce-
nario, nanoparticles form a monolayer around the surface of
the microcapillary (Fig. 6b), which is not sufficient to reduce
the transmitted light and yield a drop in the grey scale pixel
intensity. Note that absorbance values are logarithmically
related to the transmitted light, meaning significant absor-
bance values require a major drop in intensify of transmitted
light. Another option in this respect is the use of fluorescence
particles.
As compared to the MCF surface, a porous substrate such
as a nitrocellulose membrane used in LF tests presents a much
larger surface area available for binding the antigen and nano-
particles. Having nominal pore sizes between 0.05 and 12 μm
[30] and with antibody-binding capacities of 80–100 μg/cm2
[31], nitrocellulose membranes enable the development of
assays with a stronger optical signal (Fig. 6c). Therefore, al-
though LF membranes lack sensitivity due to small sample
volumes, absence of flow control and autofluorescence prop-
erties [32], they present a much higher surface area compared
to many microfluidic devices, which is an advantage for par-
ticle detection. It should, however, be mentioned that despite a
much larger surface area per cm2, detection/scanning of
coloured nanoparticles used as labels is primarily restricted
to the upper part of the nitrocellulose membrane, perhaps
down to 5 to 10 μm.
4 Conclusion
Although microfluidic systems present a surface area which is
very small when compared to LF test membranes, PSA was
effectively quantified in the MCF using the silver-enhanced
gold nanoparticles, presenting a dynamic range of 10 to
100 ng/ml of PSA. Carbon nanoparticles enable the quantita-
tion of immobilized biotinylated antibody from coating solu-
tions between 10 and 40 μg/ml. The assays used a low-cost
flatbed scanner for signal detection. This study shows that
optical detection based on nanoparticle immunoassay label-
ling is possible in the MCF, which opens possibilities for
future development of rapid one-step microfluidic immunoas-
says that can be optically scanned with low-cost
ba c
Fig. 6 Optical interrogation of heterogeneous immunoassay tests. a In
the absence of any optical signal (particles or enzymatic), the transmitted
light equals the incident light, resulting in zero absorbance value. bWith
the use of colloidal carbon or gold nanoparticles, particles bound to the
inner wall of the microcapillary lead to a change of the refractive and
reduction on the transmitted light; however, strength of optical signal is
limited by the monolayer. c In a porous media like a nitrocellulose
membrane, the larger surface area available allows stronger optical
signals to be generated (transmitted or reflectance mode) when
compared to a microcapillary system
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optoelectronic components. However, this study clearly high-
lights that one-step particle detection in microfluidic systems
will require major improvements to yield similar sensitivity as
in multistep immunoassays.
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